↓ Skip to main content

HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally…

Overview of attention for article published in BMC Cancer, February 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#48 of 8,066)
  • High Attention Score compared to outputs of the same age (97th percentile)

Mentioned by

news
5 news outlets
twitter
61 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
55 Dimensions

Readers on

mendeley
84 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma
Published in
BMC Cancer, February 2018
DOI 10.1186/s12885-018-4096-0
Pubmed ID
Authors

A. Arjona-Sánchez, P. Barrios, E. Boldo-Roda, B. Camps, J. Carrasco-Campos, V. Concepción Martín, A. García-Fadrique, A. Gutiérrez-Calvo, R. Morales, G. Ortega-Pérez, E. Pérez-Viejo, A. Prada-Villaverde, J. Torres-Melero, E. Vicente, P. Villarejo-Campos, J. M. Sánchez-Hidalgo, A. Casado-Adam, Ruben García-Martin, Manuel Medina, T. Caro, C. Villar, Enrique Aranda, M. T. Cano-Osuna, C. Díaz-López, E. Torres-Tordera, F. J. Briceño-Delgado, S. Rufián-Peña

Abstract

Local relapse and peritoneal carcinomatosis (PC) for pT4 colon cancer is estimated in 15,6% and 36,7% for 12 months and 36 months from surgical resection respectively, achieving a 5 years overall survival of 6%. There are promising results using prophylactic HIPEC in this group of patients, and it is estimated that up to 26% of all T4 colon cancer could benefit from this treatment with a minimal morbidity. Adjuvant HIPEC is effective to avoid the possibility of peritoneal seeding after surgical resection. Taking into account these results and the cumulative experience in HIPEC use, we will lead a randomized controlled trial to determine the effectiveness and safety of adjuvant treatment with HIPEC vs. standard treatment in patients with colon cancer at high risk of peritoneal recurrence (pT4). The aim of this study is to determine the effectiveness and safety of adjuvant HIPEC in preventing the development of PC in patients with colon cancer with a high risk of peritoneal recurrence (cT4). This study will be carried out in 15 Spanish HIPEC centres. Eligible for inclusion are patients who underwent curative resection for cT4NxM0 stage colon cancer. After resection of the primary tumour, 200 patients will be randomized to adjuvant HIPEC followed by routine adjuvant systemic chemotherapy in the experimental arm, or to systemic chemotherapy only in the control arm. Adjuvant HIPEC will be performed simultaneously after the primary resection. Mitomycin C will be used as chemotherapeutic agent, for 60 min at 42-43 °C. Primary endpoint is loco-regional control (LC) in months and the rate of loco-regional control (%LC) at 12 months and 36 months after resection. We assumed that adjuvant HIPEC will reduce the expected absolute risk of peritoneal recurrence from 36% to 18% at 36 months for T4 colon-rectal carcinoma. NCT02614534 ( clinicaltrial.gov ) Nov-2015.

Twitter Demographics

The data shown below were collected from the profiles of 61 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 84 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 13%
Student > Ph. D. Student 10 12%
Student > Bachelor 6 7%
Other 6 7%
Student > Postgraduate 5 6%
Other 13 15%
Unknown 33 39%
Readers by discipline Count As %
Medicine and Dentistry 34 40%
Nursing and Health Professions 4 5%
Unspecified 2 2%
Biochemistry, Genetics and Molecular Biology 2 2%
Arts and Humanities 1 1%
Other 6 7%
Unknown 35 42%

Attention Score in Context

This research output has an Altmetric Attention Score of 80. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 October 2022.
All research outputs
#431,985
of 22,190,504 outputs
Outputs from BMC Cancer
#48
of 8,066 outputs
Outputs of similar age
#12,047
of 408,831 outputs
Outputs of similar age from BMC Cancer
#1
of 4 outputs
Altmetric has tracked 22,190,504 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,066 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 408,831 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them